Methods of treating or reducing the risk of cardiovascular events and related diseases using sglt-2 inhibitors

Abstract

The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.

What is claimed is: 
     
         1 - 33 . (canceled) 
     
     
         34 . A method of reducing the risk of cardiovascular disease in a human comprising administering ertugliflozin or a co-crystal thereof in a therapeutically effective amount to the human, wherein the human has type 2 or type 1 diabetes. 
     
     
         35 . The method of reducing the risk of cardiovascular disease in a human of  claim 34 , wherein the human has type 2 diabetes. 
     
     
         36 . The method of reducing the risk of cardiovascular disease in a human of  claim 34 , wherein the ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof is administered as a pharmaceutical composition. 
     
     
         37 . The method of reducing the risk of cardiovascular disease in a human of  claim 36 , wherein, the pharmaceutical composition comprises from 0.1 to 500 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof. 
     
     
         38 . The method of reducing the risk of cardiovascular disease in a human of  claim 36 , wherein, the pharmaceutical composition comprises from 1 to 200 mg. 
     
     
         39 . The method of reducing the risk of cardiovascular disease in a human of  claim 36 , wherein, the pharmaceutical composition comprises from 2 to 100 mg. 
     
     
         40 . The method of reducing the risk of cardiovascular disease in a human of  claim 36 , wherein, the pharmaceutical composition comprises from 2 to 20 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof. 
     
     
         41 . The method of reducing the risk of cardiovascular disease in a human of  claim 36 , wherein, the pharmaceutical composition comprises 5 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof. 
     
     
         42 . The method of reducing the risk of cardiovascular disease in a human of  claim 36 , wherein, the pharmaceutical composition comprises 5 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof. 
     
     
         43 . The method of reducing the risk of cardiovascular disease in a human of  claim 36 , wherein, the pharmaceutical composition is administered once daily. 
     
     
         44 . A method of reducing the risk of cardiovascular death in a human comprising administering ertugliflozin or a co-crystal thereof in a therapeutically effective amount to the human, wherein the human has type 2 or type 1 diabetes. 
     
     
         45 . The method of reducing the risk of cardiovascular death in a human of  claim 44 , wherein the human has type 2 diabetes. 
     
     
         46 . The method of reducing the risk of cardiovascular death in a human of  claim 44 , wherein the ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof is administered as a pharmaceutical composition. 
     
     
         47 . The method of reducing the risk of cardiovascular death in a human of  claim 46 , wherein, the pharmaceutical composition comprises from 0.1 to 500 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof. 
     
     
         48 . The method of reducing the risk of cardiovascular death in a human of  claim 46 , wherein, the pharmaceutical composition comprises from 1 to 200 mg. 
     
     
         49 . The method of reducing the risk of cardiovascular death in a human of  claim 46 , wherein, the pharmaceutical composition comprises from 2 to 100 mg. 
     
     
         50 . The method of reducing the risk of cardiovascular death in a human of  claim 46 , wherein, the pharmaceutical composition comprises from 2 to 20 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof. 
     
     
         51 . The method of reducing the risk of cardiovascular death in a human of  claim 46 , wherein, the pharmaceutical composition comprises 5 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof. 
     
     
         52 . The method of reducing the risk of cardiovascular death in a human of  claim 46 , wherein, the pharmaceutical composition comprises 5 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof. 
     
     
         53 . The method of reducing the risk of cardiovascular death in a human of  claim 46 , wherein, the pharmaceutical composition is administered once daily.